Human Papilloma Virus (HPV) vaccination in Italy: towards new perspectives and new challenges

Authors

  • Vittoria Colamesta Università Cattolica del Sacro Cuore, Roma
  • Adriano Grossi Università Cattolica del Sacro Cuore, Roma
  • Andrea Barbara Università Cattolica del Sacro Cuore, Roma
  • Anna Acampora Università Cattolica del Sacro Cuore, Roma
  • Francesco Andrea Causio Università Cattolica del Sacro Cuore, Roma
  • Giovanna Elisa Calabrò chiara.dewaure@unipg.it
  • Chiara de Waure University of Perugia

DOI:

https://doi.org/10.2427/13021

Abstract

Human Papilloma virus (HPV) is the cause of a sexually transmitted infection which can lead to the development of genital warts, anogenital and oropharyngeal cancers. In Europe, about 90% of HPV-related cancers and 90% of genital warts are estimated to be vaccine preventable each year. In Italy, around 5,000 cases of cancers are due to HPV infections each year. This explains why HPV infection control is considered a public health priority.

Downloads

Published

2022-02-15

Issue

Vol. 15 No. 4 (2018)

Section

Editorial

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.